The clinical use of recombinant human Growth Hormone (rhGH) or its secretagogues to treat specific endocrine deficiencies or to address age-related decline in physiological function. In a clinical setting, application is strictly indicated for diagnosed Growth Hormone Deficiency (GHD) in adults, which is distinct from the age-related decline in GH known as somatopause. The therapeutic goal is to restore metabolic and somatic function, including improved body composition and bone mineral density.
Origin
Growth Hormone (GH) was first isolated from human cadavers, and its therapeutic use began in the mid-20th century. The advent of recombinant DNA technology in the 1980s allowed for the large-scale production of rhGH, making widespread clinical application possible. The study of its effects on adult metabolism and aging led to the controversial and highly regulated application in longevity medicine.
Mechanism
Administered GH binds to specific receptors on target cells, notably hepatocytes, stimulating the production of Insulin-like Growth Factor 1 (IGF-1). IGF-1 then acts as the primary mediator of GH’s anabolic effects, promoting protein synthesis, lipolysis (fat breakdown), and skeletal muscle growth. This cascade of signaling is central to the hormone’s role in tissue repair, metabolic regulation, and maintaining youthful body composition.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.